Banlota, Daisy A.
HRN: 15-36-30 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/14/2024
CLINDAMYCIN 150MG/ML, 4ML (AMP)
07/14/2024
07/21/2024
IV
600mg
Q8h
Breast Mass, Invasive Ductal Carcinoma
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes